Direct Detection of ESKAPE Pathogens From Whole Blood Using T2MR Bacteria Panel in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis

Status: Unknown
Study Type: Observational
SUMMARY

Our prospective observational study focuses on the rapid detection of etiologic agents of pyogenic spondylodiscitis and infective endocarditis using the T2 Bacteria Panel (T2Biosystems). This diagnostic method combines polymerase chain reaction (PCR) and T2 magnetic resonance for detection of bacterial DNA from whole blood samples. It detects six pathogens known by the acronym ESKAPE (E. coli, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecium). In recent years, similar studies using the Bacteria Panel and Candida Panel have been performed in patients with bloodstream infections, leaving us with optimistic results.The aim of this study is to verify whether T2B can identify the etiologic agents of localized infections, specifically spondylodiscitis and endocarditis, with better sensitivity and specificity and shorter time to result compared to conventional diagnostics from blood culture. Rapid detection of pathogen may reduce time to targeted pathogen-specific antibiotic therapy and subsequently improve outcomes, shorten the treatment and contribute to slowing the development of antibiotic resistance.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Diagnosis of spondylodiscitis or/and facet joint infection or/and sacroileitis

• Diagnosis of infective endocarditis

• Antibiotic treatment not received or not longer than 24 hours

• Ability to give informed consent

Contact Information
Primary
Lucie Cíchová, MD
lucie.cichova@protonmail.com
+420728781647
Time Frame
Start Date: 2022-09-01
Completion Date: 2025-09-01
Participants
Target number of participants: 50
Treatments
T2Bacteria Panel positive
Patients with spondylodiscitis and endocarditis who had positive T2Bacteria Panel test.
Sponsors
Collaborators: Bulovka Hospital, University Hospital, Motol
Leads: Charles University, Czech Republic

This content was sourced from clinicaltrials.gov